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Abstract
Aims/hypothesis Type 1 diabetes results from the autoimmune
destruction of insulin-secreting pancreatic beta cells by Tcells.
Despite the established role of T cells in the pathogenesis of
the disease, to date, with the exception of the identification of
islet-specific T effector (Teff) cells, studies have mostly failed
to identify reproducible alterations in the frequency or func-
tion of T cell subsets in peripheral blood from patients with
type 1 diabetes.
Methods We assessed the production of the proinflammatory
cytokines IL-21, IFN-γ and IL-17 in peripheral blood mono-
nuclear cells from 69 patients with type 1 diabetes and 61
healthy donors. In an additional cohort of 30 patients with
type 1 diabetes and 32 healthy donors, we assessed the
frequency of circulating T follicular helper (Tfh) cells in
whole blood. IL-21 and IL-17 production was also mea-
sured in peripheral blood mononuclear cells (PBMCs)
from a subset of 46 of the 62 donors immunophenotyped
for Tfh.
Results We found a 21.9% (95% CI 5.8, 40.2; p=3.9×10−3)
higher frequency of IL-21+ CD45RA−memory CD4+ Teffs in
patients with type 1 diabetes (geometric mean 5.92% [95% CI
5.44, 6.44]) compared with healthy donors (geometric mean
4.88% [95% CI 4.33, 5.50]). Consistent with this finding, we
found a 14.9% increase in circulating Tfh cells in the patients
(95% CI 2.9, 26.9; p=0.016).
Conclusions/interpretation These results indicate that in-
creased IL-21 production is likely to be an aetiological factor
in the pathogenesis of type 1 diabetes that could be considered
as a potential therapeutic target.
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Immunophenotyping . T follicular helper cell . Type 1
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Introduction
Type 1 diabetes is a T cell mediated autoimmune disease
characterised by exogenous insulin dependency resulting
from the destruction of the insulin-producing beta cells.
Pathogenesis of type 1 diabetes involves the breakdown of
tolerance, autoantibody production and the activation of islet
antigen-specific autoreactive CD4+ Tcells that in turn provide
help for islet antigen-specific CD8+ cytotoxic T cell responses
[1–3]. Genetic association studies in type 1 diabetes have
identified risk variants in the key genes responsible for auto-
immune responses against insulin-derived peptides (HLA
class II and class I genes, and the insulin gene), as well as in
genes with prominent roles in CD4+ T cell function. Several
studies have investigated proinflammatory Th1/Th17 re-
sponses in type 1 diabetes patients, reporting a Th17 bias
among type 1 diabetes patients as compared with healthy in-
dividuals [4–8]. CD4+ Tcells purified from the blood of newly
diagnosed type 1 diabetes patients were skewed towards IL-17
secretion when compared with healthy controls [5, 6]; and
monocytes from type 1 diabetes patients were shown to spon-
taneously secrete the proinflammatory cytokines IL-6 and IL-
1β that induce Th17 cells [4]. There is evidence from mouse
models for a role of the IL-21 pathway in type 1 diabetes [9],
but aside from the established IL2-IL21 region association
with type 1 diabetes risk [10], we have only identified one
published, recent study that reported increased frequencies
of circulating CD4+ T follicular helper (Tfh) cells together
with enhanced expression of IL-21 in type 1 diabetes patients
[8]. This contrasts with several reports of increases in Tfh
frequencies in other autoimmune diseases such as Sjogren’s
syndrome, systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), myasthenia gravis, autoimmune thyroid dis-
ease, juvenile dermatomyositis and multiple sclerosis [11].
In the present study, we have characterised the production
of the key proinflammatory cytokines IL-21, IL-17 and IFN-γ
in the peripheral T cell compartment of 69 type 1 diabetes
patients and 61 healthy donors. We report here an increased
production of IL-21 and, to a lesser extent, IL-17, but not
IFN-γ, in memory CD4+ T effector (Teff) cells from type 1
diabetes patients as comparedwith healthy controls. Consistent
with the increased production of IL-21, we also report an in-
creased frequency of peripheral Tfh from an independent co-
hort of 30 long-standing type 1 diabetes patients and 32 healthy
controls. Collectively, these findings suggest that Tfh cells and
IL-21-mediated inflammation are involved in the pathogenesis
of type 1 diabetes.
Methods
Participants Adult long-standing type 1 diabetes patients (n=
20) and healthy controls (n=21) were recruited from the
Cambridge BioResource (CBR; www.cambridgebioresource.
org.uk). Newly diagnosed type 1 diabetes patients (n=49) and
unaffected siblings (UAS) of other type 1 diabetes probands
(n=40) were collected from the JDRF Diabetes–Genes,
Autoimmunity and Prevention (D-GAP) study (http://
paediatrics.medschl.cam.ac.uk/research/clinical-trials/).
Newly diagnosed patients were characterised as having
been diagnosed with type 1 diabetes within less than
2 years (with one exception of 42 months) and UAS
were islet autoantibody-negative, and were not related
to any type 1 diabetes patient included in this study.
All donors were of white ethnicity and all healthy
controls were individuals without autoimmune disease
(self-reported).
For the Tfh cell immunophenotyping in whole blood, an
independent cohort of 30 adult long-standing type 1 diabetes
patients and 32 healthy controls, were recruited from the CBR.
Baseline characteristics for all participating individuals are
summarised in Table 1.
Ethics All samples and information were collected with writ-
ten and signed informed consent. The D-GAP study was ap-
proved by the Royal Free Hospital & Medical School
Research Ethics Committee; REC (08/H0720/25). Adult
long-standing type 1 diabetes patients and healthy volunteers
were enrolled in the CBR. The study was approved by the
local Peterborough and Fenland Research Ethics Committee
(05/Q0106/20).
Peripheral blood mononuclear cells (PBMCs) sample
preparation PBMCs were isolated by Ficoll gradient centri-
fugation (Lympholyte; Cederlane, Burlington, NC, USA) and
cryopreserved in 10% (vol/vol) heat-inactivated human
AB serum (Sigma-Aldrich, St Louis, MO, USA), as de-
scribed previously [12]. Of note, type 1 diabetes patients
and healthy controls were recruited contemporaneously
and samples were processed and stored by the same inves-
tigators to prevent spurious findings caused by differential
sample preparation.
Cryopreserved PBMCs (10×106 per donor) were thawed
in a 37°C water bath and resuspended in X-Vivo (Lonza,
Basel, Switzerland) +1% (vol/vol) heat-inactivated, filtered
human AB serum. Cell viability following resuscitation was
assessed in PBMCs from a subset of 40 donors using the
Fixable Viability Dye eFluor 780 (eBioscience, San Diego,
CA, USA) and was found to be consistently very high (medi-
an 95.6%; min 86.8%, max 98.2%) for all samples collected
as part of the cohorts analysed in this study.
Cell culture and in vitro stimulation To reduce the effects of
experimental variation and other potential covariates, PBMC
samples were processed in batches of a minimum of ten sam-
ples per day. Type 1 diabetes patients and healthy controls
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were matched as closely as possible for age (within 5 year age
bands), sex and time of sample preparation.
After thawing, PBMCs were resuspended in RPMI medi-
um (Gibco, Paisley, UK) supplemented with 10% (vol/vol)
FBS, 2 mol/l L-Glutamine and 100 μg/ml Pen-Strep and cul-
tured (106 PBMCs/well) in 24-well flat-bottom cell culture
plates (BD Biosciences, San Diego, CA, USA). Cells were
initially rested for 30 min at 37°C and then activated with
(1) 50 ng/ml phorbol myristate acetate (PMA; Sigma-
Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) for 5 h
at 37°C for IL-21 production assays; or (2) with 5 ng/ml PMA
and 100 ng/ml ionomycin for 4 h at 37°C for IL-17 and IFN-γ
production assays. For both stimulation conditions, 0.67μl/ml
BD GolgiStop (monensin, BD Biosciences) was added prior
to cell culture. For selected samples, 106 cells were cultured
with medium alone and 0.67 μl/ml monensin to determine
background levels of cytokine production in unstimulated
cells. For a subset of 39 samples assessed in the later two
batches, IFN-γ- and IL-17-producing cells were also assessed
in parallel using a higher stimulation condition (10 ng/ml
PMA and 500 ng/ml ionomycin).
We included one unstimulated sample in each batch, which
was used to assess staining of IL-21, IL-17 and IFN-γ, and set
the gate for cytokine-positive cells. As expected in these short-
term cultures, we observed little production of cytokines in
unstimulated sells (Electronic Supplementary Material
[ESM] Fig. 1).
The concentrations of PMA and ionomycin used for
in vitro stimulation in this study were optimised to ensure
optimal cytokine production and minimal cell death. Even at
the highest activation condition used in this study (50 ng/ml
PMA and 500 ng/ml ionomycin for 5 h), cell viability was
found to be sufficient for analysis (median 80.8% live cells;
min 37.2%, max 94.3%) following cell culture and in vitro
stimulation.
Intracellular immunostaining After activation, PBMCs were
harvested, and stained with Fixable Viability Dye eFluor 780
for 20 min at 4°C. Cells were then stained with fluorochrome-
conjugated antibodies against surface receptors (see Table 2)
for 1 h at 4°C. Fixation and permeabilisation was performed
using forkhead box protein 3 (FOXP3) Fix/Perm Buffer Set
(BioLegend, San Diego, CA, USA) and cells were then
stained with the respective intracellular antibodies or isotype
control antibody for 1 h at 4°C (see Table 2).
Tfh cell surface immunostainings For the Tfh cell
immunophenotyping, up to two adult long-standing type 1
diabetes patients and at least one age- and sex-matched
healthy donor were recruited on the same day from the
CBR.Whole blood was collected by venipuncture and stained
within 2 h of collection with fluorochrome-conjugated mono-
clonal antibodies (Table 2) for 40 min at 4°C. Erythrocytes
were then lysed and the white blood cells fixed for 10 min at
room temperature using BD FACS lysing solution (BD
Biosciences).
Flow cytometry Immunostained samples were acquired using
a BD Fortessa (BD Biosciences) flow cytometer with
FACSDiva software (BD Biosciences). Flow cytometry data
Table 1 Baseline characteristics of study participants
Cohort n Age (years) Male n (%) Duration of disease (months)
Median Range Median Range
Cytokine production in T1D patients and healthy controls (PBMCs)
T1D (D-GAP)a 49 13 6–34 32 (65.3%) 11 2–42
T1D (CBR)b 20 32 22–42 8 (40.0%) 198 6–276
T1D (combined) 69 14 6–42 40 (58.0%) 22 2–276
Unaffected relatives (D-GAP) 40 13 6–31 21 (52.5%) N/A N/A
Healthy controls (CBR) 21 27 18–37 7 (33.3%) N/A N/A
Healthy controls (combined) 61 15 6–37 28 (45.9%) N/A N/A
T follicular helper cell immunophenotyping (whole blood)c
T1D (CBR) 30 32 22–47 9 (30.0%) 204 24–240
Healthy controls (CBR) 32 32 17–52 9 (28.1%) N/A N/A
Baseline characteristics for the study participants stratified by the study cohorts
a Newly diagnosed T1D patients (duration of disease ≤3 years) enrolled in the D-GAP study
b Long-standing adult type 1 diabetes patients enrolled from the CBR
c Twenty-three of the 62 CBR donors selected for Tfh cell immunophenotyping were also assessed for the cytokine production phenotypes
N/A, not applicable; T1D, type 1 diabetes
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were exported in format 3.0 and analysed using FlowJo (Tree
Star, Ashland, OR, USA). Compensation controls were gen-
erated using CompBeads (BD Biosciences) compensation
beads. Cyto-Cal calibration beads (Thermo Fisher Scientific,
Waltham, MA, USA) were used to assess instrument stability.
Dead-cell exclusion based on the Fixable Viability Dye was
performed for the intracellular immunostainings.
Statistical analyses Statistical analyses were performed using
Prism software (GraphPad, La Jolla, CA, USA) and Stata
(www.stata.com). Association of the assessed cytokine
production phenotypes with type 1 diabetes was calculated
by linear regression including batch as a covariate. The
effects of age, sex and time of collection on the association
with type 1 diabetes were dealt by the experimental design
used in this study and, therefore, not included as additional
covariates. Given that most cytokine production phenotypes
showed moderate to strong right skew that violated the
assumption of normality, the phenotypes were log-
transformed (natural log) before statistical testing. Three do-
nors (two type 1 diabetes patients and one healthy donor) were
found to carry a known polymorphism in PTPRC (CD45),
which reduces production of the alternatively spliced mRNA
encoding the CD45RO isoform in memory cells thereby in-
creasing the expression of CD45RA on this subset. Since the
delineation of most assessed phenotypes depended on the sur-
face expression of CD45RA, these three donors were exclud-
ed from the analysis.
The frequency of circulating Tfh cells between type 1 dia-
betes patients and healthy controls was compared using an
unpaired two-tailed Student’s t test.
Results
IL-21 production is increased in CD4+memory effector Tcells
from type 1 diabetes patients We measured the production of
three major proinflammatory cytokines, IL-21 (n=114), IL-17
(n=66) and IFN-γ (n=116), by polychromatic flow cytometry
in type 1 diabetes patients and healthy controls, matched as
closely as possible for age, sex and time of sample preparation
(Table 1). All phenotypes were assessed in thawed, cryopre-
served PBMCs following in vitro activation with PMA and
ionomycin. Consistent with the age-matching of cases and
controls in this study, we observed no significant difference
in the overall frequency of memory (CD45RA−) CD4+ Teff
cells in type 1 diabetes cases compared with healthy controls
( p=0.15; ESM Fig. 2). To avoid increased variability caused
by CD4+ T cell subset heterogeneity and intra-individual
Table 2 Antibodies and immu-
nostaining panels used for flow
cytometry
Anti-human monoclonal antibod-
ies used for the T-cell
immunophenotyping
a Two clones of anti-CD25 that
bind to different epitopes were
used simultaneously to enhance
CD25 staining
AF, Alexa Fluor; APC,
allophycocyanin; BV, Brilliant
Violet; Cy, cyanine; IC, isotype
control; PB, Pacific Blue; PE,
phycoerythrin; PerCP, peridinin-
chlorophyll proteins
Immunostaining panel Antibody Fluorochrome Clone Manufacturer
IL-21 CD4 AF700 RPA-T4 BioLegend
CD25a APC M-A251 + 2A3 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA AF488 HI100 BioLegend
IL-21 (IC) PE 3A3-N2 (MOPC-21) BioLegend
FOXP3 PB 259D BioLegend
Viability dye eFluor780 – eBioscience
IFN-γ/IL-17 CD4 AF700 RPA-T4 BioLegend
CD25a APC M-A251 + 2A3 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA BV785 HI100 BioLegend
CCR6 BV605 G034E3 BioLegend
FOXP3 PB 259D BioLegend
HELIOS FITC 22F6 BioLegend
IFN-γ PE B27 BD Biosciences
IL-17 PerCP Cy5.5 BL168 BioLegend
Viability dye eFluor780 – eBioscience
Tfh cell immuno-phenotyping
(whole blood)
PD-1 PE MIH4 BD Biosciences
CD4 AF700 RPA-T4 BioLegend
CD45RA PE-Cy7 HI100 BioLegend
CD25a APC M-A251 + 2A3 BD Biosciences
CCR6 AF488 G034E3 BioLegend
CD3 eFluor780 SK7 eBioscience
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variation in the composition of the immune subsets, we have
normalised our data on the memory CD45RA− CD4+ Teff
population for IL-21 and IFN-γ and the CCR6+ subset of this
same memory population for IL-17, a chemokine receptor
expressed ubiquitously on Th17 cells [13] (Fig. 1a). We found
that the frequency of IL-21+ cells within the memory
CD45RA− Teff cell population was increased in type 1 diabe-
tes patients (geometric mean 5.92% [95% CI 5.44, 6.44])
compared with healthy donors (geometric mean 4.88% [95%
CI 4.33, 5.50], p=3.9×10−3; Fig. 1b and Table 3). This result
suggests that a larger proportion of CD4+ Teff cells from type
1 diabetes patients as compared with healthy donors have
previously secreted IL-21 in response to stimulation within
various tissues, including the islets and pancreatic lymph
nodes. The frequency of IL-21+ CD4+ Teffs was not associat-
ed with the duration of the disease, ranging from 2 months to
23 years in our patient population (p=0.78).
Production of IL-17 and IFN-γ in CD4+ memory cells of type
1 diabetes patients and healthy donors In contrast to IL-21,
there was no convincing support for a differential frequency of
IFN-γ-producing cells within the CD45RA− CD4+ T cell sub-
set ( p=0.07) in type 1 diabetes patients as compared with
controls (Fig. 1c and Table 3). To investigate if this lack of
association with type 1 diabetes was also observed under
stronger activation conditions, we also measured the produc-
tion of IFN-γ in a subset of 38 donors in whom cytokine
production was assessed using more potent PBMC stimula-
tion conditions (500 ng/ml ionomycin, instead of 100 ng/ml).
Similarly, we found no difference for the production of IFN-γ
by CD45RA− CD4+ T cells between type 1 diabetes patients
and healthy controls under these experimental conditions ( p=
0.90; Fig. 1e). We did observe an increase in the frequency of
IL-17+ cells within the subpopulation of CD45RA− CCR6+ T
cells in type 1 diabetes patients (geometric mean 4.26% [95%
CI 3.25, 5.58]) compared with healthy donors (geometric
mean 3.61% [95% CI 2.68, 4.86], p=0.04; Fig. 1d and
Table 3), which was also replicated ( p=0.03; Fig. 1f) in the
subset of 38 donors activated using different PBMC stimula-
tion conditions (500 ng/ml ionomycin).
In addition to the production of IFN-γ by CD45RA− CD4+
T cells, we also investigated its production in the subset of
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Fig. 1 IL-21 production is increased in type 1 diabetes patients. (a)
Gating strategy for the delineation of IL-21+ CD45RA−, IFN-γ+
CD45RA− and IL-17+ CD45RA− CCR6+ CD4+ memory effector T cell
subsets. (b) Scatter plot depicts the distribution (geometric mean±95%
CI) of IL-21+ cells among memory CD45RA− CD4+ T cells. The fre-
quency of IL-21+ cells was compared between 61 type 1 diabetes patients
and 53 healthy donors (p=3.9×10−3). (c, d) Scatter plots depict the fre-
quency of IFN-γ+ (c) and IL-17+ (d) cells in a sample of 62 type 1
diabetes patients and 54 healthy donors following in vitro stimulation
with 100 ng/ml PMA and ionomycin. (e, f) Frequency of IFN-γ+ (e)
and IL-17+ (f) cells was also assessed in a subset of 24 type 1 diabetes
patients and 15 healthy controls following in vitro stimulation with a
higher concentration (500 ng/ml) of ionomycin. The p values were cal-
culated by linear regression of the log-transformed data, including batch
as a covariate. Horizontal bars represent the geometric mean (±95% CI)
obtained from the transformation of the log-transformed data: (Y=exp[Y])
of each group. Additional data from the statistical analysis are provided in
Table 3. HC, healthy control; T1D, type 1 diabetic patient. *p<0.05,
**p<0.01
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CD127−CD25+ FOXP3+ regulatory Tcells (Tregs), according
to the expression of the transcription factor HELIOS (Fig. 2a).
Consistent with their regulatory phenotype, we found that the
HELIOS+ FOXP3+ Tregs did not produce the proinflammato-
ry cytokines IFN-γ and IL-17, after in vitro stimulation. In
contrast, a small proportion of the HELIOS− FOXP3+ fraction
was able to produce IFN-γ, which was pronounced in the
memory CD45RA− subset. Nevertheless, we did not observe
a difference in IFN-γ production by HELIOS− CD45RA−
FOXP3+ Tregs between type 1 diabetes patients and healthy
controls (p=0.79; Fig. 2b).
Increased IL-21 production is associated with an increased
frequency of circulating Tfh cells within the memory cell pop-
ulation in type 1 diabetes patients Since IL-21 production is
characteristic of Tfh cells, we examined the frequency of this
subset in whole blood samples from an independent cohort of
30 type 1 diabetes patients and 32 healthy donors. Consistent
with the increase in the frequency of IL-21-producing cells
within the memory CD4+ T cell subset, we observed an in-
creased frequency of Tfh cells, known to produce IL-21 and
defined as PD-1+ CCR6− cells, from CD45RA− CXCR5+
CD4+ T cells in type 1 diabetes patients (mean 29.89%
[95% CI 27.53, 32.25]) compared with age- and sex-
matched healthy controls (mean 26.02% [95% CI 23.86,
28.15], p=0.016; Fig. 3 and Table 3), suggesting that IL-21
production by Tfh cells may be an aetiological factor in a
subset of type 1 diabetes patients characterised by increased
Tfh cell frequency in the peripheral circulation.
To investigate the potential association between frequency
of circulating Tfh cells and IL-21+ memory T cells, we
measured IL-21 production in cryopreserved PBMCs from
46 (24 type 1 diabetes patients and 22 healthy controls) of
the 62 individuals who had been assessed for Tfh frequency.
Importantly, to avoid the effect of day-to-day variation asso-
ciated with cytokine production assays, we measured the fre-
quency of IL-21+ memory T cells in a single experimental
batch. In this sample, we found that frequency of Tfh cells
was associated with the frequency of IL-21+ cells (r2=0.174,
p=0.004; ESM Fig. 3), suggesting that although not the only
source of IL-21, Tfh cells contribute to the production of IL-
21 observed in our study.
In addition to investigating the potential correlation be-
tween the frequency of Tfh and IL-21+ memory T cells, we
investigated whether differential expression of IL-21 in type 1
diabetes patients could be caused by an altered Tcentral mem-
ory (Tcm) cell compartment, a subset that has been recently
found to have a higher proportion of IL-21-producing cells
compared with the T effector memory (Tem) subset [14].
Owing to compromised CD62L and CCR7 staining in cryo-
preserved PBMCs, we used CD27 as a marker of Tcm cells
[15] (ESM Fig. 4a). In these 46 donors, we found no evidence
for an altered frequency of CD27+ Tcm cells within the
CD45RA− Teff compartment (p=0.717; ESM Fig. 4b).
We also found that the frequency of IL-21+ cells among the
Tcm subset was still significantly increased in type 1 diabetes
patients (geometric mean 5.33% [95% CI 4.75, 5.98] and
4.21% [95% CI 3.81, 4.66], respectively, p=2.8×10−3; ESM
Fig. 4c). Furthermore, under our stimulation conditions both
the Tcm and Tem subsets, defined based on the expression of
CD27 on our sample of cryopreserved PBMCs, were able to
produce IL-21 (geometricmean 5.0% and 8.2%, respectively).
Table 3 Association analysis of the peripheral CD4+ T-cell compartment with T1D
Phenotype (gating strategy) n Healthy donors Type 1 diabetes patients % change
(95% CI)a
p value
n Mean frequency
(95% CI)
n Mean frequency
(95% CI)
Cytokine productionb
IL-21+ memory T cells (% of CD4+)
(CD4+ CD45RA− IL21−)
114 53 4.88% (4.33, 5.50) 61 5.92% (5.44, 6.44) 21.9% (5.8, 40.2) 3.9×10−3
IFN-γ+ memory T cells (% of CD4+)
(CD4+ CD45RA− IFN-γ+)
116 54 20.12% (17.52, 23.11) 62 16.93% (14.67, 19.52) −12.1% (−24.0, 1.7) 0.07
IL-17+ CCR6+ memory T cells (% of CD4+)
(CD4+ CD45RA− CCR6+ IL17+)
66 29 3.61% (2.68, 4.86) 37 4.26% (3.25, 5.58) 28.7% (−0.7, 65.9) 0.04
CD4+ T follicular helper cell (Tfh) frequencyc
Tfh (% of CD4+ CD45RA− CXCR5+)
(PD-1+ CCR6−)
62 32 26.02% (23.86, 28.15) 30 29.89% (27.53, 32.25) 14.9% (2.9, 26.9) 0.016
The p values for the cytokine production phenotypes were calculated by linear regression, including batch as a covariate, comparing the mean frequency
of the assessed cytokine production phenotypes in type 1 diabetes patients and healthy donors matched as closely as possible for age, sex and time of
sample preparation
a Percent change and 95% CI of the respective T cell phenotype in type 1 diabetes patients relative to healthy donors
b Statistical tests for the cytokine production phenotypes were performed on log-transformed data because some phenotypes showed a strong right skew.
Mean frequencies represent the geometric means obtained from the transformation (Y=exp[Y]) of the log-transformed data (natural log)
c The p value for the Tfh cell immunophenotyping was calculated using an unpaired two-tailed Student’s t test
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Taken together, these data indicate that our observed increase
in the frequency of IL-21+-producing cells within the
CD45RA−memory Teff cell subset is not caused by an altered
composition of the CD45RA− memory Teff compartment in
type 1 diabetes patients.
Discussion
Systemic alterations in the peripheral immune system of au-
toimmune disease patients have proved challenging to identi-
fy, particularly in organ-specific autoimmune diseases such as
type 1 diabetes, in which onset of the first disease symptoms,
namely autoantibodies, can precede clinical diagnosis by
many years. In the present study, following in vitro stimula-
tion, we detected an increased proportion of IL-21-producing
cells within the memory CD4+ Teff population in type 1 dia-
betes patients. IL-21 is a well-established Tfh cytokine that
plays a major role in the generation of germinal centre
reactions and antibody production [16], and Tfh cell differen-
tiation has been previously shown to be negatively regulated
by IL-2 [17–19]. As a consequence, the demonstration of
increased IL-21 production in type 1 diabetes patients sup-
ports the findings from genetic studies of type 1 diabetes im-
plicating a dysfunction of the IL-2 signalling pathway in the
pathogenesis of the disease [20–22]. It will be important to
determine if the variants mapping to the IL2-IL21 region that
influence susceptibility to type 1 diabetes and other autoim-
mune diseases [10, 23–25] directly influence IL-2 or IL-21
production in a cell-intrinsic manner. In addition to promoting
B cell responses, IL-21 has also been shown to be an impor-
tant factor for the differentiation of the Th17 lineage [6, 26,
27]; therefore, the increase in IL-17-producing cells in type 1
diabetes patients as compared with healthy controls observed
in the current study, as well as in previous studies [4–6], could
be a consequence of increased IL-21 production. Results from
a recent study emphasised the pleiotropic nature of IL-21: IL-
21 promoted Th17 lineage differentiation and IL-10 produc-
tion while inhibiting Th1 differentiation as well as the
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generation of potentially pathogenic Th1/17 effector cells
[14]. How these influences on T cell differentiation and effec-
tor function by IL-21 interact in an in vivo setting and con-
tribute to autoimmune disease pathogenesis, especially bal-
anced against the ability of IL-21 to promote B cell differen-
tiation and antibody production, requires further investigation.
A limitation of the current study is that we are not able to
provide a functional mechanism to support the suggested in-
volvement of IL-21 in the aetiology of the disease. This ques-
tion will need to be addressed in future mechanistic studies
designed at characterising circulating Tfh cells in human type
1 diabetes patients in vivo, and exploring the clinical out-
comes associated with the subset of type 1 diabetes patients
with increased Tfh cell frequency and increased IL-21 levels.
An intriguing possibility is that the effect of inherited genetic
risk variants leading to deficient regulation of IL-2 signalling
are manifested in the increased production of IL-21 by Tfh
cells. Previously, we showed that variants in IL2RA that pre-
dispose to type 1 diabetes reduce the level of IL-2RA/CD25
on Tregs and memory Teff cells [20, 22], thereby potentially
increasing the amount of homeostatic IL-2 production re-
quired for Treg survival and function, and limiting Tfh
differentiation.
Overall, our findings underscore an inherent bias towards a
proinflammatory response in type 1 diabetes patients and po-
tentially reflect alterations of the immune system observed in
the autoimmune microenvironment, which are critically de-
pendent on IL-21 signalling [28]. In agreement with this
hypothesis, we show that the frequency of Tfh cells is in-
creased on average by 14.9% in type 1 diabetes patients com-
pared with controls, consistent with a recent study [8]. The
relevance of this Tfh phenotype to type 1 diabetes pathogenesis
is strongly supported by previous reports showing increased
levels of Tfh cells in seven other autoimmune diseases [11].
Their increased prevalence in the circulation in other diseases
also reduces the possibility that this Tfh phenotype, as well as
the increased IL-21 production in type 1 diabetes patients
shown here and previously reported [8], are a consequence of
insulin treatment, a potential confounding factor in type 1 dia-
betes case–control studies. One of the strongest type 1 diabetes
associated loci, PTPN22, may also be implicated in Tfh cell
responses and IL-21 production leading to an increase in B cell
numbers and antibody production in Ptpn22 knockout mice
[29]. It is plausible that the increased frequency of circulating
Tfh cells is directly responsible for the increased IL-21 produc-
tion observed in type 1 diabetes patients. Of the 62 donors
recalled for Tfh immunophenotyping, we were able to measure
the frequency of IL-21+ CD45RA− T cells in 46 of them, and
found a modest correlation between the frequencies of circu-
lating Tfh and IL-21 CD45RA− memory T cells. These data
suggest that, although Tfh cells are likely an important source
of this cytokine, there are also additional cell types that also
contribute to IL-21 production, as previously described [11].
In contrast to IL-21 and, to a lesser extent IL-17, we found
no evidence for the differential expression of the proinflam-
matory cytokine IFN-γ in type 1 diabetes patients. This lack
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of association was observed not only among CD45RA− CD4+
Teff cells, but also among a subset of HELIOS− CD45RA−
FOXP3+ CD4+ T cells. The ability of HELIOS− FOXP3+
CD4+ T cells to produce IFN-γ is consistent with similar ob-
servations by McClymont et al who reported that HELIOS−
FOXP3+ CD4+ Tregs produced increased levels of IFN-γ in
type 1 diabetes cases [7].
In summary, we have identified an imbalance in IL-21 pro-
duction in type 1 diabetes patients, which is accompanied by
an increased frequency of circulating Tfh cells. Although this
imbalance in the periphery is only manifested in a 21.9%
increase in the frequency of IL-21+ effector memory CD4+
T cells in patients, it is likely the reflection of a much larger
effect on secondary lymphoid organs, particularly at disease
diagnosis. In mice, IL-21 inhibits T cell IL-2 production and
impairs Treg homeostasis [30]. Taken together with findings
in other autoimmune diseases [11], there is genetic and immu-
nological rationale for the initiation of clinical trials to inves-
tigate the safety and efficacy of anti-IL-21 therapy in RA
patients (www.clinicaltrials.gov - NCT01565408 and
NCT01647451) and in other diseases, including type 1 diabe-
tes. Interestingly, B cell depletion with a course of anti-CD20
therapy (rituximab) decreased circulating IL-21 levels and the
frequency of Tfh cells in peripheral blood of type 1 diabetes
patients, and preserved beta cell function in ten out of 20
patients [8]. The authors proposed that the observed effects
of anti-CD20 reflect close interactions between Tfh and B
cells in germinal centres. For example, in mice, IL-21 is a
potent inducer of the co-stimulatory molecule CD86 on B
cells thereby promoting antigen presentation [31]. In light of
previous evidence of some clinical efficacy of anti-CD20 ther-
apy in type 1 diabetes patients [32], it is possible that pre-
selected patients stratified on the basis of increased levels of
IL-21, Tfh cells or with multiple circulating autoantibodies
and IFN-γ production [33] could benefit to a greater extent
from clinical interventions, such as B cell depletion, IL-2 re-
placement or anti-IL-21 therapy.
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